Effects of etoricoxib on the pharmacokinetics of phenytoin.
Journal Title: Pharmacological Reports - Year 2008, Vol 60, Issue 2
Abstract
Etoricoxib is presently the most commonly prescribed cyclooxygenase-2 (Cox-2) inhibitor for chronic pain and inflammatory conditions. In clinical practice, phenytoin and etoricoxib are used in chronic conditions of generalized seizure with concomitant chronic pain. Hence, there are chances of drug-drug interaction because modulations of isoenzymes involved in metabolism CYP2C9/10 and CYP2C19 which partially inhibited by etoricoxib. It is important to maintain the therapeutic level of phenytoin in plasma for effective control of seizure. So, the aim of the study was to determine the effect of etoricoxib on the pharmacokinetics of phenytoin in rabbits. In a parallel design study, phenytoin (30 mg/kg/day) was given daily for seven days. On day 7, blood samples were taken at various time intervals between 0-24 h. In etoricoxib group, phenytoin was administered for seven days as above. On day 8, etoricoxib (5.6 mg/kg) along with phenytoin (30 mg/kg/day) was administered and blood samples were drawn as above. Plasma phenytoin levels were assayed by HPLC and pharmacokinetic parameters were calculated. In etoricoxib group, there was a decrease in t(1/2)a phenytoin and t(1/2)el decreased significantly as compared to phenytoin group. Significant changes were observed in the pharmacokinetic parameters in etoricoxib-treated group. These results suggest that etoricoxib alters the pharmacokinetics of phenytoin. Confirmation of these results in human studies will warrant changes in phenytoin dose or frequency when etoricoxib is co-administered with it.
Authors and Affiliations
Bikash Medhi, Manpreet Sukhija, Ajay Prakash, Sumedh Gaikwad, Vishal Bansal, Promila Pandhi
Keywords
Related Articles
- EP ID EP107597
- DOI -
- Views 126
- Downloads 0
Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues.
The potential antioxidant activity of diphenhydramine (histamine H(1)-receptor antagonist) and famotidine (histamine H(2) receptor antagonist) was studied. Diphenhydramine inhibited the spontaneous, Fe(II)-induced and Fe...
Professor Alfons Chodera, Ph.D., M.D. (1925-2005).
Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays.
Over recent years, the 5-hydroxytryptamine6 (5-HT6) receptor has emerged as a promising molecular target which interacts with several central nervous system acting drugs. In animal models, both agonists and antagonists o...
Impact of the changes in P-glycoprotein activity on domperidone pharmacokinetics in rat plasma.
The effect of quinidine (QD) and grapefruit juice (GFJ) extract, P-glycoprotein inhibitors, on the domperidone (DOM) concentration in rat plasma was investigated. DOM, a dopamine D(2)-receptor antagonist is a substrate f...
Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice.
The aim of the present study was to examine the effect of mirtazapine (MIR) and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J m...